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1. Introduction  
Iron oxide nanoparticles are responsible to magnetic field allowing them to be manipulated, 
tracked, imaged and remotely heated. Such key features open up a wide field of applications 
in medicine which includes cell separation, magnetic force-based tissue engineering, MRI 
tracking of transplanted cells, magnetic drug targeting and hyperthermia.  
In most applications reported in the literature, magnetic systems are typically composed of 
an inorganic core and an organic coating. Although cores have been made from different 
materials, iron oxide nanoparticles constituted of magnetite (Fe3O4) and maghemite (γ-
Fe2O3) are used at a great extent. While the core provide nanocontainers with magnetic 
properties, the shell functions to (i) protect against core agglomeration, (ii) provide chemical 
handles for the conjugation of drug molecules, and (iii) limit opsonization. Additionally, 
shell coatings have been engineered to enhance pharmacokinetics and tailor in vivo fate. 
Organic shells main comprise phospholipid bilayered membranes or polymeric coating of 
dextran, for instance. Magnetic system design with such different materials can be achieved 
via a number of approaches, including in situ coating, post-synthesis adsorption and end-
grafting. In fact, several methods have been proposed for their synthesis, coating, and 
stabilization, mainly comprising the precipitation route together with a surface 
functionalization step by means of polymers or surfactants. This point will be the focus of 
the next chapter section – “Producing magnetic particles.”  
Once produced, these magnetic carriers must meet certain criteria for use in the human 
body. For therapeutic purposes, magnetic carriers must be water-based, biocompatible, 
biodegradable, and nonimmunogenic. Besides, special care should be focused on the particle 
size, surface properties, magnetic properties, and administration route, as will be discussed 
in the third chapter section, entitled “Magnetic particles: concerns towards in vivo use.”  
The fourth chapter section comprises the applications of magnetic particles in the field of 
biotechnology. They can be divided into therapeutic and diagnostic ones. Chapter 
subsections will focus on both. Also discussed is a novel application of magnetic 
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nanoparticles – the use of magnetic force for tissue engineering, termed “magnetic force-
based Tissue Engineering (Mag-TE).” Since cells labeled with magnetic nanoparticles can be 
manipulated using magnets, this novel tissue engineering methodology using magnetic 
force and functionalized magnetic nanoparticles may hold great promise in reproducing in 
vitro patterned tissues for organ regeneration. 
The fifth and last section of this chapter provides concluding remarks while addressing 
future perspectives in regard to magnetic particles in biotechnology. 
2. Producing magnetic particles 
2.1 Synthesis of magnetic carriers 
In most applications reported in the literature, iron oxides, such as magnetite and 
maghemite, are the magnetic material of choice. The synthesis, coating, and stabilization of 
such particles will be discussed below. The most common synthetic route to produce 
magnetite (Fe3O4) is the coprecipitation of hydrated divalent and trivalent iron salts in an 
alkaline medium (A. K. Silva et al., 2008).  
Nanoreactors can be employed for the precipitation reaction. They provide a constrained 
domain, which limits the growth of the particles. This method offers numerous advantages 
over the previous ones when higher homogeneity of size and shape are concerned.  A 
discussion of these follows. 
Microemulsions are colloidal nano-dispersions of water in oil (or oil in water) stabilized by a 
surfactant film. The synthesis of magnetic particles by this means is carried out when water 
droplets interact and exchange their contents. Experimental results have confirmed that the 
microemulsion method allows good control of the particles by preventing their growth and 
providing particles small enough to get stable magnetic fluids. On the other hand, magnetic 
particles prepared by coprecipitation may undergo aggregation. Microemulsions, which are 
thermodynamically stable dispersions, can be considered as truly nanoreactors that can be 
used to carry out chemical reactions and, in particular, to synthesize nanomaterials. The 
main idea behind this technique is that by appropriate control of the synthesis parameters, 
these nanoreactors can produce smaller and more uniform particles than the ones produced 
by other standard methods. Particle size was found to depend on the molar ratios of water 
and surfactant (Lopez-Quintela, 2003).   
Liposomes are also used as nanoreactors for the precipitation as they provide a constrained 
domain, which limits the growth of the particles. Alternatively, encapsulation of magnetic 
particles into liposomes may be performed after synthesis (A. A. Kuznetsov et al., 2001). 
Magnetoliposomes have been found to be a promising approach that offers some unique 
advantages when the magnetic nanoparticles are applied in biological systems. Lipid 
systems present the advantage of low toxicity due to their composition, mainly 
physiological lipids, compared to the polymeric particles. In fact, encapsulation of the 
magnetic nanoparticles in liposomes increases their biocompatibility under physiological 
conditions, making them suitable for a large variety of biological applications. Furthermore, 
it is known that magnetic particles tend to agglomerate, and are chemically unstable with 
respect to oxidation in air. Encapsulation of the magnetic nanoparticles in liposomes 
protects them from aggregation and oxidation (Heurtault et al., 2003).  
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Concerning the production of polymer-based magnetic carriers, three different methods 
may be used. The emulsification/polymerization method has been successfully employed to 
produce magnetic microcapsules. In this process, particles are synthesized in the internal 
aqueous phase of an inverse emulsion/microemulsion. Afterwards, polymerization by a 
cross-linking agent takes place. In such microcapsules, the drug and the magnetic particles 
are in the inner compartment (Saravanan et al., 2004). Alternatively, polymer-covered 
magnetic particles can be produced by in situ precipitation of magnetic materials in the 
presence of a polymer that acts as a stabilizer.  
Magnetic polymer nanoparticles have been produced in the presence of water-soluble dextran, 
poly (vinyl alcohol), sodium poly (oxyalkylene di phosphonates), carboxymethyl starch, and 
amylose starch, just to name a few. In all cases, magnetic particles are surrounded by a 
hydrophilic polymer shell. Such systems are functionalized by the introduction of chemical 
groups so that they are able to bind active molecules. For instance, dextran-coated magnetic 
particles, which are highly hydrophilic, uniform, and nontoxic magnetic carriers, may be 
activated by the periodate oxidation method. Thus, magnetic polyaldehyde dextran is formed 
and may be conjugated to different molecules (Hong et al., 2004).  
Another method for producing magnetic polymer particles consists of separately 
synthesizing magnetic particles and polymer particles and then mixing them together to 
enable either physical or chemical adsorption of the polymer onto the magnetic material to 
be achieved (É. L. Silva et al., 2009). 
3. Magnetic particles: Concerns towards in vivo use 
For therapeutic purposes, magnetic carriers must be water-based, biocompatible, 
biodegradable, and nonimmunogenic (Häfeli, 2004; A. K. Silva et al., 2007a). Concerning the in 
vivo use, the following parameters are critical: (a) particle size, (b) surface characteristics of the 
particle, (c) concentration of the fluid, (d) volume of the fluid, (e) administration route, (f) 
duration/rate of the injection/infusion, (g) geometry and strength of the magnetic field, (h) 
duration of magnetic field application, (i) particle stability, and (j) magnetic properties. 
Physiological parameters of the patient organism are also important. They comprise: a) size, 
weight, and body surface, (b) blood volume, (c) cardiac output and systemic vascular 
resistance, d) circulation time, (e) tumor volume and location, (f) vascular content of target 
area, and (g) blood flow in that area (A. A. Kuznetsov et al., 1999; Lübbe et al., 1999).  
Markedly, size is a crucial factor. Large microspheres can physically irritate the surrounding 
tissue or even embolize small blood vessels and capillaries. Besides, stable suspensions of 
dense particles larger than 2μm are rarely prepared, and it is difficult to inject suspensions 
of such particles through a catheter. On the other hand, very small particles (less than 0.1 
μm in diameter) have a small magnetic moment. In such a case, magnetic forces may not be 
high enough to counteract the linear blood-flow rates in the tissue. As a consequence, the 
magnetic field may fail in successfully concentrating particles at the target organ, with also 
the possibility of a significant fraction of them accumulating in the liver (Häfeli, 2004; Lübbe 
et al., 2001).  
Surface charge is known to play an important role in blood half-lives of particles. It is 
generally agreed that highly positively and negatively charged particles present a decreased 
circulation time. In such a case, particles undergo phagocytosis, resulting in distribution 
mainly in the liver or spleen. The clearance from circulation is mediated by interaction with 
cells, especially those of the reticulo-endothelial system. Functional groups on cell surfaces 
www.intechopen.com
 Advances in Applied Biotechnology 
 
240 
alter the circulation time. A usual approach consists of grafting magnetic systems with PEG 
(polyethylene glycol), which may be achieved by the precipitation of the particles in the 
presence of this polymer. By such a technique, sterically stabilized carriers are produced due 
to the induced sterical hindrance, which avoids protein binding and macrophage 
recognition (Bulte et al., 1999).  
Since the particles must be effectively controlled by the applied magnetic field, their magnetic 
properties, their dispersion, and their degree of agglomeration are important. It has been 
observed that an increase in stability of the particles leads to a decrease in toxicity. Low 
coercive force will prevent aggregation of the particles prior to superimposition of the field. As 
a result, superparamagnetic particles seem to be ideal. Besides superparamagnetism, high 
magnetic susceptibility and high saturation magnetization allow the particles to be effectively 
controlled by a relatively weak field (A. A. Kuznetsov et al., 1999).  
The fate of magnetic particles also depends strongly on the administration route: 
3.1 Intravenous administration 
After intravenous administration, smaller particles are subject to rapid renal elimination or 
are removed by cells capable of endocytosis (i.e., by B and T lymphocytes), while larger ones 
undergo uptake by the liver, spleen, and bone marrow. The blood half-lives of many iron 
oxide nanoparticles administered in patients vary from 1 h to 24–36 h (Corot et al., 2006).  
Iron oxide particles present low toxicity and are well tolerated in the human body. Inside 
the cells, such systems are expected to be degraded relatively fast. In fact, degradation into 
iron (Fe) and oxygen is presumed to occur in intracellular lysosomes of macrophages under 
the influence of a variety of hydrolytic enzymes, low pH, and protein mobilization and 
utilization according to natural Fe pathways. The human body contains around 3–4 g of Fe, 
for example, in the proteins ferritin, hemosiderin, transferritin, and hemoglobin. As the 
magnetic nanoparticles start to break down, any soluble Fe becomes part of this normal Fe 
pool, which is then regulated by the body. A clinical dose would likely include just a few 
milligrams of Fe per kilogram of body weight, which is low compared to the total 
participating in Fe metabolism. Iron oxides have been shown to degrade in vivo and 
integrate Fe stores in the human body. Therefore, they are not expected to be toxic to the 
organism (Mornet et al., 2004). This assumption concerning the low toxicity was confirmed 
by the lethal dose LD50 of magnetic systems. For instance, the LD50 of dextran–iron oxide 
complex was found to be 2000–6000 mg of Fe kg–1 of body mass. Besides, the systemic 
safety of several iron oxide nanoparticles has been evaluated after injection in humans, 
indicating that these products have a satisfactory safety profile according to standard 
toxicological and pharmacological tests (Corot et al., 2006). 
3.2 Subcutaneous and intratumoral administration 
Small particles injected locally infiltrate into the interstitial space around the injection site and 
are gradually absorbed by the lymphatic capillaries into the lymphatic system. For this reason, 
subcutaneously or locally injected (intratumoral administration) nanoparticles can be used for 
lymphatic targeting, i.e., as a tool for chemotherapy against lymphatic tumors or metastases. In 
order to achieve a good uptake in regional lymph nodes following subcutaneous injection, 
colloidal carriers should be small (60 nm or smaller) and the surface of the particles should be 
neither too hydrophilic nor too hydrophobic. Concerning intratumoral administration, 
different studies indicate its feasibility (Hilger et al., 2002, 2005). 
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3.3 Oral administration 
Magnetic particles exhibit strong potential as externally modulated oral systems for both in 
vivo imaging and targeted drug delivery. In this approach, imaging agents or drugs can be 
localized to specific sites through the application of an external magnetic field. Similarly to the 
other routes of administration, the fate of the particles in the gastrointestinal tract is closely 
related to the particle size. Particles under 5 μm can be removed via lymphatic drainage, 
particles up to 500 nm can cross the membrane of epithelial cells through endocytosis, and 
particles less than 50 nm can achieve the paracellular passage between intestinal epithelial 
cells. The use of the magnetic force to delay the transit of orally administered drugs may 
become an attractive strategy for enhancing the efficacy of orally delivered systems. Despite 
the promising properties, magnetic particles may dissolve in acid media (Silva-Freitas et al., 
2011). Such possible particle loss could reduce the efficiency of the magnetic system used as a 
drug carrier.  In order to avoid it, magnetic particles may be coated using polymers to protect 
them from the gastric environment. Our recent studies have shown that xylan and  
Eudragit®S100 coatings are able to protect magnetite from the gastric pH, successfully 
preventing particle degradation   (A. K. Silva et al., 2007b; É. L. Silva et al., 2009).  
4. Applications of magnetic particles in the field of biotechnology 
4.1 The therapeutic applications 
4.1.1 Magnetic drug targeting 
One of the major problems related to drug administration is the difficulty in targeting a 
tissue or an area of the body. After administration, drugs tend to distribute to various 
organs in a process that occurs depending on the physicochemical properties of the 
molecule. In order to reach an acceptable therapeutic level at the desired site, large amounts 
of the drug must be administered. However, only a part of the dose will actually reach the 
intended tissue or disease site, while the other fraction can cause toxic side effects at non-
target organs (Häfeli, 2004; A. K. Silva et al., 2010). 
Magnetic drug targeting (MDT) presents a solution to this problem by using magnetic 
particles as controllable carriers of therapeutic agents which are either encapsulated or 
attached to the surface of these particles (Mangual et al., 2011). Due to its non-invasiveness, 
high efficiency, quick-impact, and reduced toxicity in the non-target regions, many 
researchers are engaging in this area (Cao et al., 2011). 
MDT typically uses an external magnetic field source to capture and retain magnetic drug 
carrier particles at a specific site after being administered in the body. The accumulation of 
the magnetic particles in the desired area depends on the interplay of the magnetic forces, 
fluid resistance, and diffusive motions (Cao et al., 2011).   
There are some significant limitations of MDT. One limitation is the gradient problem, once 
the retention of the magnetic particles is quite low due to the relatively weak nature of the 
magnetic force, which must overcome the hydrodynamic force (A. K. Silva et al., 2006). It 
can be difficult to use external magnets to target areas deep within the body by the fact that 
the strength of the magnetic field generated from a permanent magnet decreases sharply 
with distance (Mangual et al., 2011).  
An approach to overcome this limitation uses implant assisted-MDT that takes advantage of 
a magnetic implant placed inside the body that can become magnetized in the presence of 
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an external magnet creating a localized magnetic field around the implant and increasing 
the magnetic force on nearby magnetic particles (Mangual et al., 2011).  
In addition, magnetic properties and the internalization of particles depend strongly on the 
size of the magnetic particles. Some hydrodynamic parameters, such as blood flow rate, 
particle concentration and infusion route play significant roles. Also, there are several forces 
acting on magnetic particles in a viscous environment and magnetic field, such as magnetic 
force due to all field sources, viscous drag force, inertia, gravity, thermal kinetics, particle 
fluid interactions and inter-particle effects such as magnetic dipole interactions, electric 
double layer interactions, and van der Waals force (Babincova & Babinec, 2009). 
The possibilities of MDT applications have drastically increased in recent years. In the 
clinical area of human medicine, these particles are being used as delivery systems for 
several drugs, mainly chemotherapy drugs. Such approach may represent a new method to 
treat cancer. Also, MDT has been used in radiotherapy and immunotherapy. Fig. 1 
demonstrates a schematic MDT model for cancer treatment (Alexiou et al., 2011). 
 
Fig. 1. Schematic drawing of MDT for tumor treatment. Reprinted from the Journal of 
Magnetism and Magnetic Materials, Vol 323, C Alexiou, R Tietze, E Schreiber, R Jurgons, H 
Richter, L Trahms, H Rahn, S Odenbach, S Lyer, Cancer therapy with drug loaded magnetic 
nanoparticles--magnetic drug targeting, 1404-1407, Copyright (2011), with permission from 
Elsevier. License number 2690150177916. 
Our research group has developed a new technology for oral delivery of drugs for the 
treatment of Helicobacter pylori infections. The focus of this work was the development of a 
stomach-specific formulation of amoxicillin based on drug-containing Eudragit®S100 
microparticles with a magnetite core. This could be the first attempt to prepare a magnetic 
system for local delivery of antibiotics, in particular for the treatment of H. pylori infections 
(É. L. Silva et al., 2009). 
4.1.2 Magnetofection  
Several systems, including viral and non-viral carriers, have been developed to transfer 
foreign genetic material into cells with the aim of enhancing gene transfer in vitro and in 
vivo. Viral vectors can provide a high transfection rate and a rapid transcription of the 
genetic material inserted in the viral genome. However, viral carriers present potential 
problems for patients, such as the immunogenicity of the viral proteins, lack of desired 
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tissue selectivity, potential for oncogenesis due to chromosomal integration, and generation 
of infectious viruses due to recombination.  
Non-viral vectors are less immunogenic, are easy to produce in large scale and capable of 
delivering large genetic material, exhibit enhanced biosafety, and can be associated with 
tissue targeting. However, unlike viral analogues that have evolved to overcome cellular 
barriers and immune defense mechanisms, non-viral gene carriers exhibit significantly 
lower transfection efficiency compared with the viral ones. Among the non-viral vectors, the 
most used compounds are cationic and biodegradable polymers, lipids, liposomes, and 
niosomes (He et al., 2010).  
In order to overcome those disadvantages, a new transfection method called magnetically 
guided gene transfection or magnetofection has been developed. Magnetofection employs 
magnetic nanoparticles combined with transfection agents to form magnetic gene vectors so 
that the vectors can be rapidly concentrated on the surface of target cells under the attraction 
of a magnetic field (Yunfeng, 2010). 
Since  the  first  reports on  magnetically  enhanced nucleic acid delivery, it has become a 
well-established method  and  has  been  predominantly  used to potentiate viral and  non-
viral gene delivery. The nucleic acids can be directly associated with magnetic nanoparticles 
in naked form or can be incorporated into a complex composed of magnetic particles and 
other components, e.g., cationic lipids and polymers. Fig. 2 shows the principle of 
magnetofection in vitro (Schillinger et al., 2005). 
 
Fig. 2. Illustration of magnetofection in cell culture. The magnetic force pulls magnetic 
nanoparticles with surface-bound gene vectors toward the cells and results in rapid kinetics 
and high efficiency nucleic acid delivery. Reprinted from the Journal of Magnetism and 
Magnetic Materials, Vol 293, U Schillinger, T Brill, C Rudolph, S Huth, S Gersting, F Krötz, J 
Hirschberger, C Bergemann, C Plank, Advances in magnetofection--magnetically guided 
nucleic acid delivery, 501-508, Copyright (2005), with permission from Elsevier. License 
number 2690150501010. 
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The magnetofection process has substantial advantages over traditional transfection 
methods. The process time is substantially reduced; high transfection rates can be obtained 
with lower vector doses; an increase in the gene transfer efficiency can be reached; and gene 
delivery can be achieved with non-permissive cells. The association of gene vectors with 
superparamagnetic nanoparticles under a magnetic field can boost the efficiency of many 
vector types up to several hundred-fold and this technique is available for most gene 
vectors. The accumulation of the vectors in the target area and the dose–response 
relationship with a smaller amount of DNA required for sufficient gene expression can be 
enhanced by magnetofection methods (Holzbach et al., 2010). 
4.1.3 Magnetic embolization 
The conventional cancer treatment is based on chemotherapy and radiotherapy, which are 
effective treatment, but these systemic approaches typically have an effect on both healthy 
and disease tissues (Yang et al., 2011). Therefore, it is necessary to study novel strategies to 
eradicate cancer cells. An alternative approach to overcome these disadvantages is magnetic 
embolization, which is a new technique in cancer therapy presenting less toxicity than 
chemotherapy and less invasiveness than surgery.  
Magnetic embolization consists of injecting (in a blood vessel) a magnetorheological (MR) 
fluid, which is a suspension of micron-sized magnetizable particles such as Fe or iron oxide 
particles (e.g., magnetite). The microscopic structures of these fluids change in the presence 
of a magnetic field, which leads to a phase transition from a liquid to a solid. MR fluids 
solidify only under a magnetic field. A seal is formed, which mechanically blocks the tumor 
blood vessels, causing its death. Once the field is removed, thermal energy makes the fluid 
return to its original liquid state (J. Liu et al., 2001). 
Flores and Liu showed that blocking the fluid flow is possible within a single-tube system, 
simulating one blood vessel. They found that the seal remains stable even at pressures 
exceeding those found inside human arterioles and capillaries (Flores et al., 1999; J. Liu et al., 
2001). Despite some promising results, it is difficult to obtain selective embolization of small 
blood vessels when these are positioned at a large distance from the magnetic field source 
(e.g., approximately >3 cm inside the body of the patient). In this case, a suitable magnetic 
field intensity and gradient in the vicinity of the vessel is required (A. K. Silva et al., 2010). 
A possible solution to this problem may be obtained by a new approach referred to as 
magnetic resonance navigation (MRN). This has been proposed to steer and track in real time 
endovascular magnetic carriers in deep tissues to target areas of interest (Pouponneau et al., 
2010), and restrain the systemic carrier distribution. MRN is achieved with a clinical magnetic 
resonance imaging (MRI) scanner upgraded with an insert of steering coils. Therefore, MRN 
can overcome the problem of a weaker magnetic field in deep tissues observed with an 
external magnet. By controlling chemoembolic material distribution, MRN could improve 
embolization and drug concentration in the tumor area while limiting chemoembolization of 
healthy blood vessels and the hepatic complications (Kennedy et al., 2010).  
MRN significantly controlled the distribution of these therapeutic particles as compared to 
the control. More importantly, a decrease in the TMMC (Therapeutic Magnetic Microcarrier) 
levels in the untargeted lobe was obtained. Steering efficiency was higher with the left 
steering compared to the right steering. Therefore, MRN was more efficient in preserving 
the right liver lobe from the chemoembolization than left lobes. Only one-third of the 
TMMC dose reached the right lobe without steering because of the natural difference in 
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blood supply between the lobes (the right lobes have less weight than left lobes) 
(Pouponneau et al., 2011) (Fig. 3). Thus, further work is necessary to confirm the feasibility 
of MRN applied to magnetic embolization. 
 
Fig. 3. Representation of MRI targeting with PLGA microparticles loaded with the doxorubicin 
and magnetic FeCo nanoparticles for liver chemoembolization. Images A and C are 
fluoroscopy images of the rabbit hepatic artery with superposed images of the microparticle 
distribution without (A) and with (C) the MRI targeting. On image A, the microparticles are 
released from the catheter in the artery and distributed to both lobes. Image B illustrates a 
schematic representation of a cut of the microparticles loaded with an antitumor drug and 
magnetic nanoparticles embedded into a biodegradable matrix. Image C displays the MRI 
targeting of the left bifurcation using the magnetic force (Fmag) to preserve the right lobe from 
the chemoembolization. Reprinted from Biomaterials, Vol 32, P Pouponneau, J-C Leroux, G 
Soulez, L Gaboury, S Martel, Co-encapsulation of magnetic nanoparticles and doxorubicin into 
biodegradable microcarriers for deep tissue targeting by vascular MRI navigation, 3481-3486, 
Copyright (2011), with permission from Elsevier. License number 2690150825494. 
4.1.4 Tissue engineering 
Advances in cell therapy research gave rise to a fast-growing multidisciplinary field that 
integrates knowledge of engineering, biology and medicine. Tissue engineering (TE) is a 
promising technology for overcoming the organ transplantation limitations related to organ 
donor shortage. It consists of appropriately using cells, materials, and physics/biochemical 
processes to restore, maintain, or improve tissue function (Fig. 4). 
 
Fig. 4. Schematic picture of tissue engineering. The combination of a scaffold, cells and 
soluble factors facilitate the formation of structural and functional tissue units. 
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Despite successful efforts and results, tissue-engineered constructs lack structural 
complexity. Well-defined spatial cell organization is required in the attempt to reproduce 
living tissue complexity and succeed in creating functional tissue constructs.  In this regard, 
several cell patterning methods such as microcontact printing and lithography have been 
developed. However, these methods demand specialized surfaces to be used as substrates 
and fabrication is time consuming. In order to bypass these shortcomings, innovative active 
patterning approaches have been based on the use of an external force. This constraint may 
be generated by an electric field, as in the dielectrophoresis technique, or by an optical trap. 
Alternatively, Ino et al. (Ino et al., 2007, 2008) suggested the use of magnetic force to induce 
two-dimensional patterning of magnetically-labeled cells on submillimetric scales. 
This group developed a novel methodology for cell patterning using magnetic force and 
magnetite cationic liposomes (MCLs), which contain 10 nm magnetite nanoparticles. MCLs 
were used as carriers to introduce magnetite nanoparticles into target cells since the 
positively charged particle surface interacts with the negatively charged cell surface. Given 
that cells labeled with magnetic nanoparticles can be manipulated by using a magnet, they 
were able to  seed labeled cells onto a low-adhesive culture surface through the use of 
magnetic force to form a tissue construct (Ino et al., 2007). This technique was designated 
magnetic force-based tissue engineering (Mag-TE). By using it, complex cell patterns 
(curved, parallel, or crossing motifs) were successfully fabricated from several cell types (Ino 
et al., 2007). This group also showed that magnetically labeled keratinocytes were 
accumulated using a magnet, and stratification was promoted by a magnetic force to form a 
sheet-like 3D construct. Transmission electron microscopy revealed the presence of 
intercellular adhesion proteins, desmosomes, within keratinocyte sheets constructed by 
Mag-TE. This result indicated that the proposed method enabled intercellular contact and 
preserved adhesion proteins. For this reason, patterns were found to resist after magnetic 
force removal and manipulation was also feasible. 
Following a related approach, Frasca et al. applied magnetic forces to create a 3D cell 
assembly with tuneable size and controlled geometry. Cells were magnetically labeled using 
anionic citrate-coated iron oxide nanoparticles. Focalized magnetic force ensured an efficient 
entrapment of the cells at the magnet vicinity. This technology could be applied with no 
restriction regarding the physicochemical nature of the substrate, the cell type, or the 
geometry of the imposed magnetic constraint (Frasca et al., 2009). The same group 
demonstrated that magnetic force-assisted cell seeding provided effective cell seeding into 
3-D porous scaffolds. Moreover, precise spatial cellular organization inside the scaffold 
could be achieved by means of magnetic microtips that develop high magnetic forces. 
4.1.5 Magnetic hyperthermia  
Hyperthermia is a technique that increases the temperature of the local environment of a 
tumor, resulting in changing the physiology of diseased cells and finally leading to 
apoptosis. Depending on the degree of temperature rise, hyperthermia treatment can be 
classified into different types. In thermo ablation, a tumor is submitted to high temperatures 
of heat >46 °C (up to 56 °C), causing cells to undergo direct tissue necrosis, coagulation, or 
carbonization. Moderate hyperthermia (41 °C <T< 46 °C) has various effects both at the 
cellular and tissue levels. Diathermia uses lower temperatures (T<41 °C) for the treatment of 
rheumatic diseases in physiotherapy. 
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During moderate hyperthermia, which is traditionally termed hyperthermia treatment, cells 
undergo heat stress resulting in activation and/or initiation of many intra- and extracellular 
degradation mechanisms, including induction and regulation of apoptosis, signal 
transduction, multidrug resistance, and heat shock protein expression. The tissue-level 
effects include pH changes, perfusion, and oxygenation of the tumor microenvironment 
(Santos-Marques et al., 2006).  
Nevertheless, traditional hyperthermia treatment presents several challenges: 1) 
unavoidable heating of healthy tissue resulting in burns, blisters, and discomfort; 2) limited 
penetration of heat into body tissues; and 3) thermal under-dosage in the target region, a 
nearly unsolved problem in the case of bone of the pelvis or scull, which shields deep 
tissues, often yielding recurrent tumor growth (Tanaka et al., 2005).  
Improvements in this technique yielded the magnetic hyperthermia treatment, which has a 
number of advantages compared to conventional hyperthermia treatment: 1) cancer cells 
absorb magnetic nanoparticles (MNPs), therefore increasing the effectiveness of 
hyperthermia by delivering therapeutic heat directly to them; 2) MNPs can be targeted 
through cancer-specific binding agents, making the treatment much more selective and 
effective; 3) the frequencies of oscillating magnetic fields generally utilized pass harmlessly 
through the body and generate heat only in tissues containing MNPs; 4) MNPs can also 
cross the blood-brain barrier, and thus can be used for treating brain tumors; 5) effective and 
externally stimulated heating can be delivered at cellular levels through alternating 
magnetic fields; 6) stable MNPs can be administered through a number of drug delivery 
routes; 7) MNPs used for hyperthermia are only a few tens of nanometer in size and 
therefore allow easy passage into several tumors whose pore sizes are in the 380–780 nm 
range; 8) compared to macroscopic implants, MNP-based heat generation is much more 
efficient and homogeneous; 9) MNP-based hyperthermia treatment may induce antitumoral 
immunity (Ito et al., 2005); and 10) the last but most important aspect is that MNP-based 
hyperthermia can also be utilized for controlled delivery of drugs (Lu et al., 2005). This 
additional feature opens up possibilities for the development of multifunctional and multi-
therapeutic approaches for treating a number of diseases. 
For MNP-based hyperthermia, a general procedure involves the distribution of particles 
throughout the targeted tumor site, followed by generation of heat to the tumor using an 
external AMF. The absorption efficiency of any material to generate heat due to AMF is 
measured in terms of a specific absorption rate or specific loss of power. These terms are 
generally used to define the transformation of magnetic energy into heat. For a majority of 
applications, it is desirable to have higher temperature enhancement rates. 
Heat generation can be attributed to two different phenomena: relaxation and hysteresis 
loss. The relaxation is of two types: Brownian and Néel. Brownian relaxation is due to the 
physical rotation of particles within the medium in which they are placed (external 
dynamics) and is hindered by the viscosity that tends to counter the movement of particles 
in the medium. Heat generation through Néel relaxation is due to rapidly occurring changes 
in the direction of magnetic moments relative to crystal lattice (internal dynamics). This is 
hindered by the energy of anisotropy that tends to orient the magnetic domain in a given 
direction relative to crystal lattice. For intracellular magnetic fluid hyperthermia, Néel 
relaxation is the major contributor for heat release (Hergt & Dutz, 2007). 
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A number of types of magnetic nanomaterials have been investigated for magnetic 
hyperthermia. Some of the well-known hyperthermic agents based on iron oxide are 
magnetite and maghemite nanoparticles. Recently, a high heating performance of 1300–
1600W/g was reported based on FeCo metallic nanoparticles (Nojima et al., 2010). However, 
iron oxide-based MNPs continue to attract attention due to their lack of toxicity, excellent 
biocompatibility, and metabolization, which is carried out by heme oxygenase-1 to form 
blood hemoglobin and hence maintain Fe cell homeostasis in cells. In addition, magnetite 
was found to be superior to cobalt nanoparticles with respect to its high Curie temperature, 
saturation magnetization (90–98 emu/g), and lower toxicity in preclinical tests (Martina et 
al., 2008).  
In vivo studies using magnetic hyperthermia have been conducted by Matsuoka et al. 
(Matsuoka, 2004). They have developed magnetic cationic liposomes based on 
superparamagnetic iron oxide nanoparticles and investigated their in vivo efficacy for 
hyperthermia treatment of hamster osteosarcoma. Magnetoliposomes were injected directly 
into the osteosarcoma and then subjected to an alternating magnetic field. The tumor was 
heated above 42°C, and complete regression was observed in 100% of the treated hamsters. 
Therefore, these results demonstrate the feasibility of magnetic hyperthermia. 
4.2 The diagnostic uses 
4.2.1 MRI contrast agent 
MRI is a noninvasive and sensitive technique to obtain images by non-ionizing radiation. As 
it associates rapid in vivo acquisition of images, long effective imaging window, fine signal 
intensity contrast, high temporal and spatial resolution, and simultaneous information 
about physiology and anatomy of the desired area, MRI quickly became one of the major 
tomographic imaging modalities (G. Liu et al., 2011).  
The images formed are the result of several parameters such as proton density, relaxation 
times (T1, T2, T2*), water diffusion, nuclear alignment, radio frequency excitation, spatial 
encoding, etc., providing a digital representation of tissue characteristics. The relative 
difference between the signal intensity of two adjacent regions is called contrast, and this 
difference is translated using a color scale (normally the grey scale for MRI). The spin–lattice 
(1/T1 = R1) and spin–spin (1/T2 = R2) relaxation rates of the water protons in tissues, which 
are the most important intrinsic factors for contrast, are dependent upon the local 
environment of the protons, so that different tissues will relax at different rates (Yurt & 
Kazanci, 2008). However, for specific studies of evaluation at the molecular and cellular 
level, the MRI sensibility is lower, being necessary the use of a contrast agent or even a 
selective binding attached to a contrast agent, in order to differentiate the target area 
(Lalatonne, 2010). 
Contrast agents are normally defined based on their relaxation properties, their magnetic 
properties, and their biodistribution. When defining a contrast agent based on relaxation 
properties, the efficiency is described by the longitudinal and transverse relaxivity R1 and 
R2, respectively. The relaxivity reflects the change in the relaxation rate as a function of the 
contrast agent concentration. The relaxivities are affected by the size and the composition of 
these particles (Yurt & Kazanci, 2008).  
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To design a contrast agent, the choice of core and monolayer material is a critical step 
because this composition determines the primary physical and chemical properties besides 
reactivity, solubility, and interfacial interactions. Most common core among the MRI 
contrast agents are paramagnetic lanthanide metals (gadolinium, manganese and 
dysprosium ion complexes) and superparamagnetic magnetite particles (iron oxides) (Yurt 
& Kazanci, 2008). Iron oxide particles are widely investigated in MRI applications as they 
alter the relaxation times of tissues in which they are present and due to the low toxicity 
when compared to gadolinium chelates (Lalatonne, 2010). In this context, the 
superparamagnetic particles, which can be superparamagnetic iron oxide (SPIO) particles, 
ultrasmall superparamagnetic iron oxide (USPIO) and oral magnetic particles (OMPs), 
appear as preferred materials because (a) they have magnetic characteristics, (b) they are 
composed of biodegradable Fe, (c) their coating can be functionalized with various ligands, 
(d) they provide the greatest signal changes per unit of metal, and (e) they are easily 
detectable by light and electron microscopy (Bulte & Kraitchman, 2004). 
Superparamagnetic iron oxides have substantially larger T2 relaxivity compared with 
gadolinium chelates in current clinical use, typically by an order of magnitude or more. This 
increase is confirmed by a superior magnetization. The T1-relaxivity can also be much 
higher for iron oxides than for gadolinium chelates. In addition, iron oxide nanoparticles 
may offer several advantages over existing agents due to their accumulation in 
macrophages combined with an intravascular distribution and higher relaxivity values 
(Bulte & Kraitchman, 2004).  
Another field of research in development aims to use superparamagnetic contrast agents in 
drug delivery applications for real-time monitoring of drug distribution to the target tissue, 
as well as to follow the effect of therapeutics on the progression of disease. 
4.2.2 Magnetic cell tracking  
There is a great need to develop improved means of monitoring transplanted cells in vivo. A 
recent methodology involves the use of magnetic particles for intracellular magnetic 
labeling of cells. This technique, called magnetic cell tracking, allows in vivo tracking of 
implanted cells via MRI. Magnetic cell tracking can be used as a non-invasive tool to 
provide unique information on the dynamics of cell movements within and away from 
tissues in vivo. Alternatively, magnetic cell tracking could be applied in the future to monitor 
cell therapy in patients. Both approaches require magnetic labeling of cells as well as 
methods for analysis and evaluation of cell labeling (Vuu et al., 2005). 
The magnetic cell tracking technique may overcome the limitations of individual in vivo 
imaging methods including low sensitivity, low resolution, or low soft tissue contrast. MRI 
provides excellent soft tissue contrast and due to its high resolution, MRI can be used for the 
visualization of single cells against a homogeneous background (Himmelreich & 
Dresselaers, 2009). 
Several methods have been developed to incorporate sufficient quantities of iron oxide 
nanoparticles into cells. These methods mainly concern the prolonged incubation of the cells 
with the particles resulting in their passive internalization. Another possibility is the 
introduction of functional ligands chemically linked to the particles, in order to increase the 
uptake by cells. Besides, the transient increase in the membrane permeability using a 
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magnetic field (magneto-electroporation) may result in a quick cytoplasmic accumulation of 
the magnetic particles (Dousset et al., 2008).  
Some other examples of magnetic cell tracking applications include labeling mesenchymal 
stem cells, haematopoietic progenitor cells, Schwann cell transplants, neural stem cells, and 
NK cells. 
4.2.3 Monitoring the gastrointestinal motility  
The evaluation of the large intestine motility is usually made by intraluminal manometry, 
radiology, or scintigraphy. Most of the current knowledge about motility of the large 
intestine was generated by intraluminal manometry. Despite its providing quantitative 
assessment, intraluminal manometry is obviously invasive and uncomfortable for patients. 
Radiology offers qualitative or, at best, semi-quantitative information, and carries the risk of 
significant radiation exposure. Gamma-scintigraphy also imposes radiation exposure and 
depends on the availability of expensive equipment (Ferreira et al., 2004). 
Among other methods, the investigation of intestinal movements by Magnetic Marker 
monitoring is considered to be a useful diagnostic tool. The colon exhibits complex motor 
patterns with variations of frequency and amplitude yielding compaction and movement of 
its contents along its extension. The arrival of a meal into the stomach is consistently 
associated with the unleashment of contractions of the large intestine, which causes 
movements of the colonic content, called gastrocolic reflex, and can be observed by an 
increase in the motor activity of the colon (Ferreira et al., 2004). 
The oral route is still by far the most common way used for the administration of 
pharmacologically active substances. This is mainly due to the ease of administration and 
the general acceptance by the patients. Knowledge about the performance of dosage forms 
in the gastrointestinal tract is essential for the choice of the optimal formulation technology 
(Weitschies et al., 2010). In order to overcome restrictions that are associated with the use of 
radioisotopes, an alternative method for the investigation of the behavior of solid dosage 
forms in the gastrointestinal tract was developed. It is based on the labeling of the dosage as 
a magnetic dipole by means of incorporation of trace amounts of ferromagnetic particles, 
recording of the magnetic dipole field using biomagnetic measurement equipment, and data 
evaluation applying techniques established in magnetic source imaging (MSI). This method 
is known as Magnetic Marker Monitoring (MMM) or Magnetic Moment Imaging (MMI). 
(Goodman et al., 2010; Weitschies et al., 1994). 
MMM is a new technique for the investigation of the gastrointestinal transit of magnetically 
marked solid drug dosage forms (Weitschies et al., 1999). The magnetic labeling of the 
dosage forms is achieved by the incorporation of small amounts of remanent ferromagnetic 
particles and their subsequent magnetization tracking. After ingestion of one magnetically 
marked dosage form, its magnetic dipole field is recorded during its gastrointestinal transit. 
Multichannel superconducting quantum interference devices (SQUID), developed for the 
detection of extremely weak biomagnetic fields, are employed for the measurement of the 
magnetic field (Drung, 1995). Finally, the parameters describing the magnetic dipole, i.e., its 
location r =(x, y, z) and its magnetic moment m=(mx, my, mz), are estimated from the 
recorded data by means of fitting procedures. After ingestion, their magnetic dipole field is 
recorded, and by means of fitting procedures, the location of the marked dosage form is 
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estimated from the recorded data.  The disintegration behavior is also assessed by this 
technique. The induction generated by the magnetic dipole moment of the oral dosage form 
during disintegration is used for the investigation of its mechanism and quantitative 
determination of the process (Weitschies et al., 2001a, 2001b). 
Additionally, MMM has been applied for the determination of the performance of 
disintegrating and non-disintegrating solid dosage forms such as tablets, capsules, and 
pellets in the gastrointestinal tract, as well as for the determination of the in vivo drug 
release from modified release products such as enteric-coated tablets and enhanced release 
tablets (Weitschies et al., 2005a).  
The combination of MMM with the pharmacokinetic measurements 
(pharmacomagnetography) enables the determination of in vitro–in vivo correlations and the 
delineation of absorption sites in the gastrointestinal tract (Weitschies et al., 2005b). The 
results obtained with MMM can also serve as a data base for the development of improved 
pharmacokinetic models. 
5. Conclusion and perspectives 
The use of magnetic particles in the medical field opens new prospect of selective 
treatment of local tissues where efficiency is increased through local concentrations while, 
at the same time, general side effects can be avoided. However, the use of magnetic 
carriers in the human body imposes several requirements on the magnetic carriers. 
Magnetic carriers must be water-based, biocompatible, biodegradable, and 
nonimmunogenic. Besides, special care should be focused on the particle size, surface 
properties, magnetic properties, and administration route, for example. In most of the 
reports in the literature, iron oxides are the material of choice for the development of 
magnetic systems for therapeutic purposes.  
Several methods have been proposed for their synthesis, coating, and stabilization. Magnetic 
systems produced by different methods have found many applications in biotechnology. 
The safety aspect, the non-invasiveness, and the high targeting efficiency are promising 
advantages for the use of magnetic particles in therapeutics. The current challenge still 
consists of totally controlling the biocompatibility, stability, biokinetics, and properties of 
the particles.  By incorporating advances in surface engineering, molecular imaging, and 
biotechnology, magnetic systems have great potential to enable physicians to diagnose and 
treat diseases with greater effectiveness than ever before. 
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